The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $62.5, a high ...

Q3 2024 Earnings Call Transcript November 5, 2024 Rhythm Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.73, expectations were $-0.8. Operator: Good day, and thank you for ...

Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) missed analyst estimates by 40%. Looking ahead, revenue ...

The group’s Chinese medicine segment primarily drove revenue, which contributed $807.8m. Tianjin Pharmaceutical Da Ren Tang ...

Revenue missed analyst estimates by 5.7%. Earnings per share (EPS) exceeded analyst estimates by 87%. Looking ahead, revenue is forecast to grow 56% p.a. on average during the next 3 years, compared ...

Reports Q3 revenue $175.7M, consensus $157.3M. The company said, “For the third quarter and first nine months of 2024, strong performance ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

Detailed price information for Exxon Mobil Corp (XOM-N) from The Globe and Mail including charting and trades.

Enticed by a reward of $1 million, a former police officer helped a foreign scam syndicate use Singapore as a conduit to ...